Analysts Set Price Target of $85.33 for Prestige Consumer Healthcare

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Moderate Buy” from eight brokerages currently covering the stock, according to data from MarketBeat.com. Among the analysts, four have rated the stock as a hold, while another four have issued buy recommendations. The average target price over the next twelve months is set at $85.33.

Several research firms have recently provided updates on Prestige Consumer Healthcare. Weiss Ratings reaffirmed a “hold” rating on October 8, 2023. On October 27, Jefferies Financial Group lowered its price target from $75.00 to $71.00 while maintaining a “hold” rating. Meanwhile, Oppenheimer decreased its target from $82.00 to $72.00 and rated the stock as outperform in a report released on October 21.

In a notable move, Sidoti upgraded Prestige from a “neutral” rating to a “buy” rating with a price objective of $80.00 on September 24. Additionally, Canaccord Genuity Group reduced its price target from $100.00 to $88.00 while maintaining a “buy” rating in their report dated November 7.

Investor Activity and Stock Performance

Prestige Consumer Healthcare has seen significant activity from institutional investors. Three Seasons Wealth LLC increased its stake in the company by 54.1% in the fourth quarter, now holding 8,573 shares valued at approximately $529,000. Similarly, Allspring Global Investments Holdings LLC raised its position by 1.3%, acquiring an additional 21,085 shares for a total of 1,613,460 shares valued at $98.78 million.

Other notable increases include Wedge Capital Management L L P NC, which raised its position by 14.6% to own 57,717 shares worth about $3.56 million. Congress Asset Management Co. lifted its holdings by 14.8%, now owning 339,018 shares valued at approximately $20.91 million. Finally, Wealth Enhancement Advisory Services LLC increased its stake by 9.4% with 9,982 shares worth around $629,000. Notably, institutional investors now own 99.95% of Prestige Consumer Healthcare’s stock.

As of Tuesday, shares of Prestige Consumer Healthcare opened at $65.13. The company maintains a quick ratio of 2.51, a current ratio of 3.70, and a debt-to-equity ratio of 0.55. Over the past year, the stock has reached a low of $57.25 and a high of $90.04. The 50-day moving average stands at $61.51, and the 200-day moving average is $65.02. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of 16.16, and a price-to-earnings-growth ratio of 2.04.

Recent Earnings Report

On November 6, 2023, Prestige Consumer Healthcare reported its earnings for the quarter, revealing earnings per share (EPS) of $1.07, exceeding the consensus estimate of $0.97 by $0.10. The company recorded a return on equity of 12.43% and a net margin of 18.09%. Revenue for the quarter totaled $274.11 million, surpassing the expected $257.14 million. This represents a 3.4% decline in revenue year-over-year, compared to earnings of $1.09 EPS during the same quarter last year.

Looking ahead, Prestige Consumer Healthcare has set its fiscal year 2026 guidance at an EPS range of 4.540-4.580. Analysts forecast the company will achieve an EPS of 4.5 for the current fiscal year, reflecting cautious optimism regarding its performance in a competitive market.

Prestige Consumer Healthcare Inc. stands as a prominent manufacturer and marketer of branded over-the-counter healthcare products. The company specializes in developing, acquiring, and commercializing a diverse portfolio of non-prescription remedies aimed at addressing common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care, and women’s health. Key brands within its portfolio include Clear Eyes, Carmex, Chloraseptic, Dramamine, Rolaids, Monistat, BC Powder, Little Remedies, and TheraTears.